Which has better earnings and valuation, IMVT or COAG?

Immunovant is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.82 N/A Hemab Therapeutics N/A N/A N/A -$24.78 N/A

Is IMVT or COAG more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Hemab Therapeutics N/A N/A N/A

Does the media prefer IMVT or COAG?

In the previous week, Immunovant had 8 more articles in the media than Hemab Therapeutics. MarketBeat recorded 10 mentions for Immunovant and 2 mentions for Hemab Therapeutics. Immunovant's average media sentiment score of 1.25 beat Hemab Therapeutics' score of 0.58 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, APGE or COAG?

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apogee Therapeutics N/A N/A -$255.84M -$4.34 N/A Hemab Therapeutics N/A N/A N/A -$24.78 N/A

Is APGE or COAG more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Apogee Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Apogee Therapeutics N/A -29.88% -28.08% Hemab Therapeutics N/A N/A N/A

Does the media favor APGE or COAG?

In the previous week, Apogee Therapeutics had 9 more articles in the media than Hemab Therapeutics. MarketBeat recorded 11 mentions for Apogee Therapeutics and 2 mentions for Hemab Therapeutics. Apogee Therapeutics' average media sentiment score of 1.63 beat Hemab Therapeutics' score of 0.58 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to COAG or TGTX?

In the previous week, TG Therapeutics had 6 more articles in the media than Hemab Therapeutics. MarketBeat recorded 8 mentions for TG Therapeutics and 2 mentions for Hemab Therapeutics. TG Therapeutics' average media sentiment score of 1.19 beat Hemab Therapeutics' score of 0.58 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is COAG or IBRX more profitable?

Hemab Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A ImmunityBio -598.55% N/A -51.65%

Does the media prefer COAG or IBRX?

In the previous week, ImmunityBio had 7 more articles in the media than Hemab Therapeutics. MarketBeat recorded 9 mentions for ImmunityBio and 2 mentions for Hemab Therapeutics. ImmunityBio's average media sentiment score of 0.61 beat Hemab Therapeutics' score of 0.58 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALKS or COAG?

In the previous week, Alkermes had 5 more articles in the media than Hemab Therapeutics. MarketBeat recorded 7 mentions for Alkermes and 2 mentions for Hemab Therapeutics. Alkermes' average media sentiment score of 0.63 beat Hemab Therapeutics' score of 0.58 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Hemab Therapeutics (COAG) Competitors

$44.84 -4.65 (-9.40%)

As of 08/28/2026 04:00 PM Eastern

Compare

COAG vs. IMVT, APGE, TGTX, IBRX, and ALKS

Should you buy Hemab Therapeutics stock or one of its competitors? Hemab Therapeutics's main competitors and comparable companies include Immunovant (IMVT), Apogee Therapeutics (APGE), TG Therapeutics (TGTX), ImmunityBio (IBRX), and Alkermes (ALKS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Hemab Therapeutics compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Hemab Therapeutics (NASDAQ:COAG) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

In the previous week, Immunovant had 8 more articles in the media than Hemab Therapeutics. MarketBeat recorded 10 mentions for Immunovant and 2 mentions for Hemab Therapeutics. Immunovant's average media sentiment score of 1.25 beat Hemab Therapeutics' score of 0.58 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant currently has a consensus price target of $44.00, indicating a potential upside of 6.80%. Hemab Therapeutics has a consensus price target of $51.40, indicating a potential upside of 14.63%. Given Hemab Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Hemab Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Hemab Therapeutics' return on equity of 0.00% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Hemab Therapeutics	N/A	N/A	N/A

47.1% of Immunovant shares are owned by institutional investors. 1.9% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Immunovant is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A

Summary

Immunovant beats Hemab Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Hemab Therapeutics compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Hemab Therapeutics (NASDAQ:COAG) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

79.0% of Apogee Therapeutics shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Apogee Therapeutics had 9 more articles in the media than Hemab Therapeutics. MarketBeat recorded 11 mentions for Apogee Therapeutics and 2 mentions for Hemab Therapeutics. Apogee Therapeutics' average media sentiment score of 1.63 beat Hemab Therapeutics' score of 0.58 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A

Hemab Therapeutics' return on equity of 0.00% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-29.88%	-28.08%
Hemab Therapeutics	N/A	N/A	N/A

Apogee Therapeutics currently has a consensus price target of $126.77, suggesting a potential downside of 6.07%. Hemab Therapeutics has a consensus price target of $51.40, suggesting a potential upside of 14.63%. Given Hemab Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Hemab Therapeutics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Apogee Therapeutics and Hemab Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Hemab Therapeutics compare to TG Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

58.6% of TG Therapeutics shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

TG Therapeutics has higher revenue and earnings than Hemab Therapeutics. Hemab Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A
TG Therapeutics	$799.54M	10.32	$447.18M	$2.74	19.68

TG Therapeutics has a net margin of 55.22% compared to Hemab Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Hemab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
TG Therapeutics	55.22%	73.49%	34.14%

Hemab Therapeutics presently has a consensus price target of $51.40, indicating a potential upside of 14.63%. TG Therapeutics has a consensus price target of $63.00, indicating a potential upside of 16.82%. Given TG Therapeutics' higher possible upside, analysts plainly believe TG Therapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, TG Therapeutics had 6 more articles in the media than Hemab Therapeutics. MarketBeat recorded 8 mentions for TG Therapeutics and 2 mentions for Hemab Therapeutics. TG Therapeutics' average media sentiment score of 1.19 beat Hemab Therapeutics' score of 0.58 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TG Therapeutics beats Hemab Therapeutics on 11 of the 12 factors compared between the two stocks.

How does Hemab Therapeutics compare to ImmunityBio?

Hemab Therapeutics (NASDAQ:COAG) and ImmunityBio (NASDAQ:IBRX) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Hemab Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
ImmunityBio	-598.55%	N/A	-51.65%

Hemab Therapeutics has higher earnings, but lower revenue than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A
ImmunityBio	$113.29M	75.31	-$351.40M	-$0.97	N/A

Hemab Therapeutics currently has a consensus target price of $51.40, indicating a potential upside of 14.63%. ImmunityBio has a consensus target price of $14.20, indicating a potential upside of 76.40%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, ImmunityBio had 7 more articles in the media than Hemab Therapeutics. MarketBeat recorded 9 mentions for ImmunityBio and 2 mentions for Hemab Therapeutics. ImmunityBio's average media sentiment score of 0.61 beat Hemab Therapeutics' score of 0.58 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

8.6% of ImmunityBio shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

ImmunityBio beats Hemab Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Hemab Therapeutics compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Hemab Therapeutics (NASDAQ:COAG) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

95.2% of Alkermes shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Alkermes has a net margin of 3.96% compared to Hemab Therapeutics' net margin of 0.00%. Alkermes' return on equity of 4.15% beat Hemab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Hemab Therapeutics	N/A	N/A	N/A

Alkermes has higher revenue and earnings than Hemab Therapeutics. Hemab Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	5.39	$241.66M	$0.38	124.76
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A

In the previous week, Alkermes had 5 more articles in the media than Hemab Therapeutics. MarketBeat recorded 7 mentions for Alkermes and 2 mentions for Hemab Therapeutics. Alkermes' average media sentiment score of 0.63 beat Hemab Therapeutics' score of 0.58 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Alkermes currently has a consensus price target of $54.56, suggesting a potential upside of 15.09%. Hemab Therapeutics has a consensus price target of $51.40, suggesting a potential upside of 14.63%. Given Alkermes' stronger consensus rating and higher possible upside, research analysts plainly believe Alkermes is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Alkermes beats Hemab Therapeutics on 14 of the 14 factors compared between the two stocks.

Get Hemab Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COAG vs. The Competition

Export

Metric	Hemab Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.09B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-1.81	11.62	273.16	25.45
Price / Sales	N/A	1,296.40	605.16	76.41
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	4.61	16.53	12.98	6.14
Net Income	N/A	-$22.80M	$3.48B	$348.86M
7 Day Performance	-8.79%	-0.31%	0.13%	-0.80%
1 Month Performance	-5.54%	9.80%	7.08%	4.13%
1 Year Performance	N/A	55.66%	24.67%	15.17%

Hemab Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COAG Hemab Therapeutics	3.0068 of 5 stars	$44.84 -9.4%	$51.40 +14.6%	N/A	$2.09B	N/A	N/A	72
IMVT Immunovant	1.362 of 5 stars	$44.37 +0.0%	$44.00 -0.8%	+180.5%	$9.16B	N/A	N/A	120	Positive News Analyst Forecast
APGE Apogee Therapeutics	1.6418 of 5 stars	$134.75 flat	$124.43 -7.7%	+271.1%	$8.38B	N/A	N/A	91	News Coverage Positive News
TGTX TG Therapeutics	3.451 of 5 stars	$54.27 +7.3%	$63.00 +16.1%	+83.9%	$8.31B	$616.29M	19.81	290	Positive News High Trading Volume
IBRX ImmunityBio	2.3025 of 5 stars	$7.79 -0.6%	$14.20 +82.3%	+244.0%	$8.26B	$113.29M	N/A	590

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COAG) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hemab Therapeutics (COAG) Competitors

COAG vs. IMVT, APGE, TGTX, IBRX, and ALKS

How does Hemab Therapeutics compare to Immunovant?

Summary

How does Hemab Therapeutics compare to Apogee Therapeutics?

Summary

How does Hemab Therapeutics compare to TG Therapeutics?

Summary

How does Hemab Therapeutics compare to ImmunityBio?

Summary

How does Hemab Therapeutics compare to Alkermes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COAG vs. The Competition

Hemab Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hemab Therapeutics (COAG) Competitors

COAG vs. IMVT, APGE, TGTX, IBRX, and ALKS

How does Hemab Therapeutics compare to Immunovant?

Does the media prefer IMVT or COAG?

Do analysts recommend IMVT or COAG?

Is IMVT or COAG more profitable?

Do institutionals & insiders have more ownership in IMVT or COAG?

Which has better earnings and valuation, IMVT or COAG?

Summary

How does Hemab Therapeutics compare to Apogee Therapeutics?

Do institutionals and insiders believe in APGE or COAG?

Does the media favor APGE or COAG?

Which has preferable earnings and valuation, APGE or COAG?

Is APGE or COAG more profitable?

Do analysts recommend APGE or COAG?

Summary

How does Hemab Therapeutics compare to TG Therapeutics?

Do institutionals & insiders have more ownership in COAG or TGTX?

Which has stronger earnings and valuation, COAG or TGTX?

Is COAG or TGTX more profitable?

Do analysts recommend COAG or TGTX?

Does the media refer more to COAG or TGTX?

Summary

How does Hemab Therapeutics compare to ImmunityBio?

Is COAG or IBRX more profitable?

Which has preferable valuation and earnings, COAG or IBRX?

Do analysts rate COAG or IBRX?

Does the media prefer COAG or IBRX?

Do insiders & institutionals have more ownership in COAG or IBRX?

Summary

How does Hemab Therapeutics compare to Alkermes?

Do institutionals and insiders hold more shares of ALKS or COAG?

Is ALKS or COAG more profitable?

Which has stronger valuation and earnings, ALKS or COAG?

Does the media refer more to ALKS or COAG?

Do analysts recommend ALKS or COAG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COAG vs. The Competition

Hemab Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools